Matthew Wake

Title: The Innovations of Matthew Wake

Introduction

Matthew Wake is an accomplished inventor based in Babraham, GB. He has made significant contributions to the field of medical science, particularly in the treatment of physiological iron overload. His innovative approach has the potential to impact the lives of many individuals suffering from related health conditions.

Latest Patents

Matthew Wake holds a patent for a treatment for physiological iron overload with an anti-matriptase-2 antibody. This patent presents antibodies to the enzyme matriptase-2 (MTP-2). Inhibiting MTP-2 reduces the uptake of dietary iron and decreases the release of iron from cellular stores in the body. The use of inhibitors of MTP-2, such as antibodies to the serine protease domain, can be instrumental in treating iron overload, which is a characteristic of diseases like beta-thalassemia. This condition can lead to toxic accumulation of iron if left untreated. Furthermore, the combination of an MTP-2 inhibitor with an activin receptor ligand trap or with erythropoietin provides additional therapeutic effects.

Career Highlights

Matthew Wake is currently associated with Kymab Limited, where he continues to advance his research and innovations. His work is pivotal in developing new treatments that address critical health issues related to iron overload.

Collaborations

Matthew has collaborated with notable colleagues, including Igor Theurl and Jonathan Leslie Papworth. Their combined expertise contributes to the advancement of innovative solutions in the medical field.

Conclusion

Matthew Wake's contributions to the field of medical science through his patent and work at Kymab Limited highlight his commitment to improving health outcomes. His innovative approaches to treating iron overload demonstrate the potential for significant advancements in medical treatments.